


Date Rpt	
Date Rcvd	
Patient	
Case No.	D4106
Path Ref#	L-03-2617
Physician	
Diagnosis	Ovarian Cancer
Prior ChemRx	No
DISC Assay	
Viable tumor cell ratio, Day 4/Day 0	1.10
% tumor cells, Day 4	99
MTT Assay	
O.D. Negative Control-Positive Control	0.34
Comments	
DISC/MTT Correlation Coefficient	0.82
Technical Quality:	Excellent



Drug or Combination	Expected (Pre-Test) ResponseRate	Assay Result	Assay Predicted Response Probability
Cyclophosphamide(4HC)	35	Intermediate	35
Melphalan	35	Intermediate	35
Carboplatin	70	Sensitive	89
Cisplatin	70	Sensitive	89
Oxaliplatin	55	Intermediate	55
Oxaliplatin+Cisplatin	70	Sensitive	89
Doxorubicin	30	Intermediate	30
Epirubicin	30	Intermediate	30
Etoposide	30	Sensitive	62
Cisplatin+Etoposide	70	Sensitive	89
Fluorouracil+Leucovorin	25	Intermediate	25
Gemcitabine (Gemzar)	30	Intermediate	30
Gemcitabine+Cisplatin	75	Sensitive	91
Gemcitabine+Oxaliplatin	70	Sensitive	89
Gemcitabine+Cyclophos(4HC)	55	Intermediate	55
Gemcitabine+Melphalan	55	Intermediate	55
Irinotecan (CPT-11)	20	Intermediate	20
Topotecan (Hycamtin)	35	Intermediate	35
Mitomycin C	20	<i>Resistant</i>	4
Taxol (Paclitaxel)	45	<i>Resistant</i>	10
Docetaxel (Taxotere)	40	<i>Resistant</i>	8
Vinorelbine (Navelbine)	30	Intermediate	30
Vinorelbine+High Dose Tamoxifen	30	Sensitive	62